Dr. X Shirley Liu is the co-founder and CEO of GV20 Therapeutics, a clinical stage immuno-oncology drug discovery company. Dr. Liu received PhD in Biomedical Informatics and PhD minor in Computer Science from Stanford University in 2002. Before joining GV20 in 2022, She has been a Professor of Biostatistics and Computational Biology at the Department of Data Science at Dana-Farber Cancer Institute (DFCI) and Harvard University. Her research focused on algorithm development and data integration modeling for understanding cancer gene regulation, cancer epigenetics, cancer immunology, cancer drug response and resistance. She published over 250 peer-reviewed papers, mentored 25 trainees to independent faculty positions, and has an H-index of 109. Dr. Liu is a fellow of the International Society of Computational Biology (ISCB), American Institute for Medical and Biological Engineering (AIMBE), and was a Breast Cancer Research Foundation Investigator (2017-2021). She is a recipient of the Sloan Research Fellowship (2008), Weitzman Outstanding Early Career Investigator Award from the Endocrine Society (2016), ISCB Innovator Award (2020), and the Benjamin Franklin Award for Open Access in the Life Sciences (2020).